GHRP-6 vs Ipamorelin: Key Differences

GHRP-6 and Ipamorelin are both growth hormone secretagogue peptides that bind the same receptor, GHS-R1a (the ghrelin receptor), but the published literature describes them with markedly different selectivity profiles: GHRP-6 also engages appetite, cortisol, and prolactin pathways, while Ipamorelin is characterized in the research as acting much more narrowly on those same secondary pathways. That difference in selectivity is why the two compounds show up in different research protocols despite sharing a pharmacological family.

What each peptide is, according to the literature

GHRP-6 (Growth Hormone Releasing Peptide-6) was one of the first synthetic secretagogues studied, dating back to the 1980s, as a ghrelin receptor agonist. In vitro and in vivo work describes it as stimulating pulsatile growth hormone release from the pituitary through a mechanism independent of the GHRH axis.

Ipamorelin is a newer molecule, designed specifically to preserve GH stimulation while reducing activation of receptors tied to appetite, cortisol, and prolactin. Papers characterizing it describe a "fourth-generation" pentapeptide within the GHRP family, built as a more selective research tool than its predecessors.

Both compounds share catalogue space with CJC-1295 without DAC, another secretagogue the literature often pairs in studies of synergistic action on the GH-IGF-1 axis, though it works through a different route — a GHRH analog rather than a ghrelin mimetic. The destination-specific documentation is on the Argentina page for CJC-1295 without DAC.

The mechanism: same receptor, different read

Both peptides are GHS-R1a agonists — the receptor that ghrelin, the endogenous hunger and GH-release hormone, normally activates. Binding that receptor in the pituitary and hypothalamus triggers release of stored growth hormone.

The difference isn't which receptor each one activates, it's how cleanly they do it. Receptor binding assays show GHRP-6 has meaningful affinity for other receptors tied to the appetite and stress axes, while Ipamorelin was optimized in the lab specifically to minimize that cross-reactivity.

Selectivity: the variable the literature keeps returning to

When papers compare the two compounds head to head, the word that recurs is "selectivity." The research describes:

• GHRP-6 measurably activating appetite-associated receptors, which in the models studied translates into increased hunger.
• GHRP-6 also being linked, across several studies, to more pronounced elevations in cortisol and prolactin than those observed with Ipamorelin.
• Ipamorelin, in comparable assay types, producing GH release of similar magnitude with much lower activation of those secondary pathways.

That's the distinction most of the literature uses to position Ipamorelin as the "cleaner" secretagogue in the GHRP family, and GHRP-6 as the more potent appetite stimulant — a property some animal models study deliberately, precisely for its orexigenic effect.

GH release potency: what the evidence actually shows

In assays that directly compare the magnitude of the GH pulse released, both peptides are effective GHS-R1a agonists, and neither clearly outperforms the other on that single parameter. The practical difference reported in the studies isn't really "how much GH does each one release," it's the rest of the activation profile — how contained the response stays to that one pathway.

That matters for anyone designing a research protocol. Choosing between the two compounds isn't a question of which releases more GH, it's a question of how specific the experimental model needs to be. A design aiming to isolate the GH-IGF-1 axis without cortisol or appetite interference will, per the literature, favor the compound with lower cross-reactivity.

Half-life and study frequency

Both are described in the literature as short-half-life peptides, which in laboratory practice means administration protocols with repeated dosing within the experimental window rather than a single exposure. That trait is shared across nearly the entire family of GH secretagogues studied to date, including Sermorelin, which works through the GHRH pathway rather than the ghrelin pathway.

Neither peptide is administered with continuous, uninterrupted exposure in the published experimental designs. Study protocols typically alternate exposure periods with compound-free periods, which is standard practice across GH-IGF-1 axis research generally.

Documentation: why the certificate matters, not the datasheet

No comparison between GHRP-6 and Ipamorelin means anything if the material that reaches the lab isn't what it claims to be. The way to verify that isn't the supplier's technical datasheet — the same party selling the compound writes that — it's the certificate of analysis (COA) from an independent laboratory, with a lot number and a stated method.

PeptoClinic publishes third-party certificates of analysis on its quality page, so they can be read directly instead of taken on the supplier's word. Before adding any secretagogue to a protocol, it's worth requesting that document and confirming the lot number matches the vial received.

Ipamorelin is available through PeptoClinic; see the product page. Prices are on the pricing page; anything not listed there can be asked about through a consultation.

Availability for research in Argentina

Shipping and documentation conditions for Argentina are on the Argentina page. Prices are on the pricing page; anything not listed there can be asked about through a consultation.

Regulatory status

None of PeptoClinic's compounds, including GHRP-6 and Ipamorelin, is approved by ANMAT or the FDA. A physician reviews every consultation before anything ships. PeptoClinic does not provide dosing guidance or administration routes.